A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Trial Profile

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2015 Pooled analysis (ACP103-020 and ACP103-012) Efficacy and tolerability results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 16 Jun 2015 According to an Acadia Pharmaceuticals media release, data from this study were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 11 Mar 2015 According to ACADIA Pharmaceuticals media release, NDA submission for pimavanserin to US FDA is likely to take place in second half of 2015; data from this trial will support regulatory submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top